Pharma Focus Asia

Radiopharm Enters into Strategic Collaboration with Lantheus and Assumes PD-L1 Licensing Agreement From Nanomab

Thursday, August 04, 2022

Radiopharm Theranostics, a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that it has entered a collaboration agreement with Lantheus for the mutually beneficial development of NM-01, a nanobody made using genetically engineered camelid derived single domain antibodies, that can be labelled with radioisotopes to potentially diagnose and treat multiple tumor types.

In a separate, concurrent agreement, Radiopharm acquired from NanoMab the imaging rights of NM-01 for the strategic Chinese market and worldwide IP rights for any therapeutic use (previously a licencing right).

Radiopharm will shortly initiate a Phase 1 therapeutic trial in Australia in patients with PD-L1 + non-small cell lung cancer (NSCLC). Radiopharm and Lantheus have agreed to cross-reference each other's data to accelerate the development plans for the PD-L1 assets, including the development and regulatory process with USA Food and Drug Administration (FDA) and other key regulatory agencies.

Lantheus provides innovative diagnostics, targeted therapeutics and artificial intelligence (AI) solutions that empower clinicians to Find, Fight and Follow disease. Lantheus holds the exclusive imaging rights to NM-01, apart from China, and recently commenced a Phase 2 clinical trial of NM-01 to evaluate PD-L1 expression in NSCLC patients.

Pursuant to the collaboration agreement, Lantheus will provide the diagnostic product candidate of NM-01 to Radiopharm for use in its therapeutic clinical trials. NM-01 will be used to assess PD-L1 expression during patient selection. In addition, under the agreement, Radiopharm and Lantheus have the option to expand their collaboration to additional assets and potential licensing opportunities in Radiopharm's pipeline.

Radiopharm's CEO & Managing Director Riccardo Canevari said:

"We are excited to have entered a strategically important relationship with Lantheus. We look forward to seeing the results of the Phase 2 PD-L1 imaging trial and to continuing our relationship with Lantheus into the future."

Lantheus' Chief Business Officer, Etienne Montagut said:

"We are pleased to enter into a strategic collaboration with Radiopharm to further the development of NM-01, our novel targeted PD-L1 imaging agent, as a clinical research tool. We believe NM-01's unique potential to evaluate patients before, during, or after treatment with checkpoint inhibitors, will assist Radiopharm in the optimization of the development of its immuno-oncology therapy."

As part of a broader collaboration with NanoMab Ltd, Radiopharm's acquisition of the NanoMab PD-L1 IP will be at no cost for Radiopharm Theranostics.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024